Moreover, IFN therapy can induce an exacerbation of various vasculitis manifestations (i.e., glomerulonephritis, neuropathy), and RBV, due to its renal elimination, may be contraindicated in patients with severe renal impairment. This evidence concerns the gene IFNA1 and neuropathy.